Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Drops By 46.4%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 120,361 shares, a drop of 46.4% from the June 15th total of 224,716 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily trading volume, of 1,909,636 shares, the days-to-cover ratio is currently 0.1 days.

Avalon GloboCare Trading Down 2.7%

Shares of NASDAQ ALBT opened at $0.26 on Wednesday. Avalon GloboCare has a 12 month low of $0.21 and a 12 month high of $4.74. The stock has a 50 day moving average of $0.33 and a 200-day moving average of $0.62. The company has a market capitalization of $3.09 million, a P/E ratio of -0.07 and a beta of -0.03.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.